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Introduction: For the identification of the patients who most likely
benefit from epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors in non-small cell lung cancer (NSCLC), molecular
assays are considered to be of paramount importance. Given the
heterogeneity of NSCLC at the molecular level, this study was
conducted to determine the discrepancy in EGFRmutations between
primary tumors and the corresponding lymph node metastasis.
Patients and Methods: Surgically resected 101 paired primary
NSCLC and metastatic lymph nodes were evaluated for the EGFR
mutations by direct DNA sequencing and heteroduplex analysis.
Results: EGFR mutation was detected in 29.7% (30 of 101) of the
primary tumors and in 27.7% of lymph node metastases (28 of 101)
by either direct sequencing or heteroduplex analysis, respectively.
By direct sequencing, 12 cases (11.9%) showed discordance in
EGFR mutations between primary tumors and metastasis. In 11
cases, EGFR mutations were detected only in the primary tumor,
whereas 1 case only in lymph node metastases. By heteroduplex
analysis, 17 cases (16.8%) were discordant. Ten cases were primary
tumor positive and lymph node negative, whereas seven cases were
lymph node positive and primary tumor negative.
Conclusions: A considerable proportion of NSCLC showed dis-
crepancy in EGFR mutations between primary tumors and meta-
static lymph nodes, suggesting tumor heterogeneity at the molecular
level during the process of metastasis.
Key Words: Non-small cell lung cancer, EGFR, Mutation, Lymph
node, Metastasis, DNA sequencing.
(J Thorac Oncol. 2009;4: 809–815)
Lung cancer is the leading cause of cancer-related mortalitythroughout the world.1 Significant advances in the under-
standing of the biology and molecular mechanism of cancer
have allowed the development of new molecularly targeted
agents for the treatment of non-small cell lung cancer
(NSCLC). The epidermal growth factor receptor (EGFR) is
overexpressed in upto 60 to 80% of the NSCLC cases, adding
to its appeal as a therapeutic target.2 The EGFR leads to
activation of various signal cascades including the phospha-
tidylinositol 3-kinase/Akt pathway, the signal transduction
Ras/Raf/mitogen-activated protein kinase pathway, and the
signal transducers and activators of transcription proteins.3,4
Gefitinib (Iressa, ZD1839; AstraZeneca Inc., London,
United Kingdom) and erlotinib (Tarceva; Roche, Basel, Swit-
zerland), small molecular EGFR tyrosine kinase inhibitors
(TKIs) that reversibly target EGFR, have demonstrated ac-
tivity in advanced NSCLC in the second-line and third-line
settings. EGFR TKIs clinical trials have shown that these
agents had clinical benefits in certain subsets of NSCLC
patients.5–7 Although the treatment with gefitinib did not
provide a statistically significant survival benefit in all pa-
tients in the Iressa Survival Evaluation in Lung Cancer trial,
a significant survival benefit was seen among never smokers
and Asians. In addition, better objective responses were
observed in never smokers, females, adenocarcinomas, and
Asians.8 In the phase III trial of erlotinib, response rates were
also higher in females, adenocarcinomas, never smokers and
Asians, although the beneficial effect of erlotinib on survival
was not limited to these subgroups.9 These results suggest
that different patients derive different degrees of clinical
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benefit from the treatment with EGFR TKIs. Therefore, an
emerging issue concerning the EGFR TKIs in NSCLC is the
identification of reliable molecular markers for selecting
patients who will most likely benefit from these agents. This
led to the discovery of somatic activating mutations in the TK
domain of EGFR that confer tumor sensitivity to TKIs.7,10
Several subsequent studies have shown that patients harbor-
ing EGFR mutations have a higher response to EGFR TKIs
therapy than those without mutations,11,12 although there
were some discrepancies about the relationship between
EGFR mutations and survival in the EGFR TKIs-treated
NSCLC patients.8,9 Recent phase III Iressa Pan-Asia study
trial comparing gefitinib monotherapy with carboplatin or
paclitaxel combination chemotherapy demonstrated im-
proved progression-free survival (PFS) in the gefitinib arm.
The subgroup analysis from 437 patients revealed the differ-
ences in PFS outcomes according to the EGFR mutations.
PFS was significantly longer with gefitinib than with carbo-
platin or paclitaxel for patients with EGFR mutations (hazard
ratio, 0.48; p  0.0001).13 These results of the Iressa Pan-
Asia study may implicate the importance of EGFR mutations
as a predictive marker in gefitinib therapy in untreated clin-
ically selected NSCLC patients. Although most patients who
undergo EGFR-targeting therapy are diagnosed at an ad-
vanced stage with metastases, EGFR status was analyzed
using primary tumors in majority of the studies.10,14 How-
ever, it is still not known whether the EGFR status deter-
mined in the primary tumors exactly reflects the EGFR status
of the metastatic tumors in NSCLC patients. It has been known
that lung cancers are often heterogeneous at the molecular level
even within the same tumor.15–17 In addition, molecular charac-
teristics might differ between the primary tumor and the metas-
tases. Therefore, in this study, we compared the EGFR muta-
tions between primary tumors and synchronous lymph node
metastases in surgically resected 101 paired specimens using
both direct DNA sequencing and a more sensitive heteroduplex
method.18
PATIENTS AND METHODS
Patients
All specimens were obtained from NSCLC patients
who underwent curative resection for excision of primary
tumor and corresponding lymph nodes metastases at the
Samsung Medical Center (Seoul, Korea) between January
1996 and January 2006. The criteria for this study were as
follows: (1) pathologically confirmed NSCLC with lymph node
metastases, (2) adequate paraffin-embedded biopsy specimen for
the analysis of EGFRmutation and other molecular markers, (3)
age 18 years, and (4) patients who had not been exposed to
TKIs. In each case, hematoxylin and eosin-stained sections of
formalin-fixed paraffin-embedded tissue of primary tumor and
corresponding synchronous lymph node metastases were re-
viewed by a pathologist to identify neoplastic area and the
amount of tumor cells. Primary tumor and lymph node
specimens were obtained from all patients by surgical resec-
tion of primary tumor with lymph node dissection according
to prevailing surgical standards.19,20 Cases with stage I
NSCLC without lymph node metastases were excluded from
this study. In total, 202 tumor specimens from 101 consecu-
tive NSCLC patients, who underwent surgery for excision of
primary tumor and corresponding lymph nodes metastases,
were investigated for molecular markers for the EGFR path-
way. All slides were coded and molecular studies were inves-
tigated without knowledge of the patient’s identity or clinical
status. This study was approved by the Institutional Review
Board at the Samsung Medical Center in Seoul, Korea, in
accordance with the Declaration of Helsinki.
Analysis of EGFR Gene Mutation
Paraffin-embedded tumor blocks or at least 10-un-
stained slides could be collected from 101 patients for mo-
lecular analysis of EGFR. Tumor cells were microdissected
and harvested with gentle scraping from five paraffin sections
of 10-m thickness containing a representative portion of
each tumor block. The genomic DNA was extracted from
primary lung cancer tissues and matched lymph node metas-
tasis using the QIAamp DNA Mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions for
mutational analysis of the EGFR gene coding sequence. DNA
concentration was determined by a spectrophotometer, and
50 ng of DNA were amplified in a 20-l reaction solution
containing 2 l of 10 buffer (Roche, Mannheim, Germany),
1.7 to 2.5 mmol/L of MgCl2, 250 M of deoxynucleotide
triphosphate, 2.5 U of DNA polymerase (Roche), and 0.3 M
of each primer pairs. The primer sequences for EGFR gene in exon
18, 19, 20, and 21 were as follows: exon 18—forward primer:
5-tccaaatgagctggcaagtg-3, reverse primer: 5-tcccaaacactcagtgaaa-
caaa-3; exon 19—forward primer: 5-atgtggcaccatctcacaattgcc-3,
reverse primer: 5-ccacacagcaaagcagaaactcac-3; exon 20—for-
ward primer: 5–cattcatgcgtcttcacctg-3, reverse primer: 5-cata
tccccatggcaaactc-3; exon 21—forward primer: 5-gctcagagc-
ctggcatgaa-3, reverse primer: 5-catcctcccctgcatgtgt-3. The
cycling conditions were as follows: initial denaturation at
94°C for 5 minutes followed by 30 cycles at 94°C for 60
seconds, 57°C for 60 seconds, and 72°C for 60 seconds, and
one cycle at 72°C for 10 minutes. The polymerase chain
reaction (PCR) products were purified by Qiagen PCR puri-
fication kit (Qiagen). Direct sequencing of the PCR products
was performed using ABI PRISM 3100 DNA Analyzer.
(Applied Biosystems, Foster City, CA). Each paired tumor
specimen was independently analyzed in a blinded fashion for
the presence of an EGFR mutation using a previously estab-
lished heteroduplex analysis (WAVE/Surveyor method).18
Briefly, DNA from EGFR exons 18 to 21 was amplified using
exon-specific primers, and the resulting PCR products were
digested with the Surveyor endonuclease. The resulting prod-
ucts were analyzed using the WAVE HS system (Trans-
genomic Inc., Cambridge, MA) as previously described.18 The
presence of deletions in exon 19 and insertions in exon 20 were
further evaluated by sizing using the WAVE alone following
exon specific PCR. Specimens that produced digestion products
were further fractionated and sequenced using the same PCR
primers. All samples which showed positive results by hetero-
duplex analysis were independently verified.
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Statistical Analysis
The Pearson 2 test was performed to determine the
relationships between EGFR mutations and baseline clinical
characteristics. To compare the EGFR mutations detected be-
tween primary tumors and corresponding lymph node metasta-
ses, Spearman’s rank correlation coefficient (Spearman’s ) was
calculated and confirmed by Pearson’s correlation test. Cor-
relation coefficient   0.7 was considered as a strong
correlation. In all tests, p  0.05 was considered to be
statistically significant. All statistical tests were two sided.
RESULTS
Patient Characteristics
A total of 125 cases with pathologically confirmed
NSCLC with synchronous lymph node metastases were an-
alyzed for EGFR mutations and other molecular markers. No
patients received EGFR-targeted therapy or chemotherapy
before their tumor specimens were obtained. Tumor speci-
mens adequate for molecular analysis of EGFR mutations for
both primary tumor and matched lymph node metastases
were available from 101 patients. The median age was 61
years (range, 32–82 years) and 72.3% were male. Stage at the
time of surgery was determined according to the tumor, node,
metastasis staging system: 49 patients (48.5%) were classified at
pathologic stage II; 46 (45.5%) at stage III; and 6 (6.0%) at stage
IV. Pathologic type was determined according to World Health
Organization criteria,21 61 tumors (60.4%) were adenocarci-
noma and 38 (37.6%) were squamous cell carcinomas. Accord-
ing to smoking history, 66 (65.4%) patients were ever smokers
and 29 (28.7%) were never smokers (Table 1).
EGFR Mutations in Primary Tumor and Lymph
Node Metastases Evaluated by Direct
DNA Sequencing
We reviewed the amount of tumor cells in each speci-
men by histopathologic examination to avoid possible false
negative results. The mean percentage of tumor cells was
79.6% (95% confidence interval, 75.7 to 83.3%) in the
samples from the primary tumors and 67.6% (95% confi-
dence interval, 64.1–71.1%) in the specimens from the met-
astatic lymph nodes, respectively. By direct sequencing,
EGFR mutations were detected in 20.8% (21 of 101 patients)
of the primary tumors and in 10.9% of the metastatic lymph
nodes (11 of 101 patients). Nine cases of in-frame deletions
in exon 19, 11 cases of amino acidic substitutions in exon 21,
and 1 case of amino acid insertion in exon 20 were detected
in the primary tumor specimens. Eleven cases with EGFR
mutations in the lymph nodes included five cases of in-frame
deletions in exon 19, five cases of amino acidic substitution in
exon 21, and one case of amino acid insertion in exon 20.
Among the amino acid substitutions, the leucin to arginine
mutation (L858R) was found most frequently. A total of
52.4% (11 of 21) of EGFR mutations in the primary lung
tumors and 36.4% (4 of 11) of EGFR mutations in the lymph
node metastasis showed L858 mutation, representing the
major hot spot mutation in the EGFR gene. Interestingly,
amino acid substitution, threonine to methionine mutation
(T790M) representing acquired resistance to targeted TKIs,
was found in one of the metastatic lymph node but not in the
primary tumor in the absence of drug selection (Table 2).
Comparison of the EGFR Mutations between
Primary Tumors and Lymph Node Metastases
by Direct DNA Sequencing
By direct sequencing, the EGFR mutations were dis-
cordant in 11.9% of paired lesions (12 of 101 cases). Eleven
cases (10.9%) showed EGFR mutations in the primary tu-
mors but not in the lymph nodes. One case (1%) showed
EGFR mutations in the lymph node but not in the primary
tumor. Spearman’s  correlation coefficient was calculated to
evaluate the correlation of the EGFRmutations in the primary
tumor and that in the lymph node metastasis. The EGFR muta-
tion in the primary tumor determined by direct DNA sequencing
was not strongly correlated to that in the lymph node metastases
(Spearman correlation coefficient   0.604, p  0.0001).
EGFR Mutations in Primary Tumor and
Lymph Node Metastases Evaluated by
Heteroduplex Analysis
Direct DNA sequencing and previously established
heteroduplex analysis methods were concomitantly success-
ful for detection of EGFR mutation in a total of 101 primary
tumors and in a total of 101 lymph-node metastases. By
heteroduplex analysis, EGFR mutations were detected in 29
of total 101 primary tumors (28.7%) and in 26 of total 101
TABLE 1. Patients’ Characteristics (n  101)
n (%)
Age, median (range) 61 (32–82)
Sex
Male 73 (72.3)
Female 28 (27.7)
Pathologic stage
II 49 (48.5)
III 46 (45.5)
IV 6 (6.0)
Pathology
Adenocarcinoma 61 (60.4)
Squamous cell carcinoma 38 (37.6)
Large cell carcinoma 1 (1.0)
Others 1 (1.0)
Histologic grade
Well differentiated 16 (15.8)
Moderately differentiated 58 (57.4)
Poorly differentiated 25 (24.8)
Unknown 2 (2.0)
Smoking history
Ever smoker 66 (65.4)
Never smoker 29 (28.7)
Unknown 6 (5.9)
AJCC Cancer Staging Manual. 6th Ed. New York: Springer, 2002. Pp. 167–181.
TNM, tumor, node, metastasis.
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metastatic lymph nodes (25.7%). Additional eight cases of
mutations in the primary tumor undetectable by direct se-
quencing were detected by heteroduplex analysis. In the
specimens of lymph nodes, 17 cases of EGFR mutations,
which were undetected by direct sequencing, were identified
by heteroduplex analysis, whereas two cases showed EGFR
mutations by direct DNA sequencing but not by heteroduplex
analysis. One case with L858R mutation by direct DNA
sequencing showed in-frame deletions in exon 19 by hetero-
duplex analysis.
By heteroduplex analysis of primary tumors, in-frame
deletions in exon 19 were detected in 15 cases (51.7%), L858
mutation in 14 cases (48.3%), and amino acid insertion in 1
case (3.4%). In one patient, in-frame deletions in exon 19,
and L858 mutation were simultaneously found. In 26 patients
with metastatic lymph nodes mutations, 13 cases (50.0%)
showed in-frame deletions in exon 19, 12 cases (46.2%)
showed L858 mutation, and 1 case (3.8%) showed amino acid
insertion in exon 20 (Table 2). In this study, eight patients
received TKIs therapy at a median time of 19.2 months
(range, 9.5–66.8 months) after surgical resection. One of eight
patients (12.5%) showed partial response to erlotinib. The pa-
tient harbored L858 mutation in both the lymph node and
primary tumor detected by both methods (P042).
TABLE 2. Mutations in the Tyrosine Kinase Domain of the EGFR Gene in Primary Tumor and Corresponding Lymph Node
Metastasis by Both Direct DNA Sequencing and Heteroduplex Analysis
No. Sex Age Pathology Smoking
Direct Sequencing Heteroduplex Analysis Tumor Cell (%)
Primary
Tumor
Lymph
Node
Primary
Tumor
Lymph
Node
Primary
Tumor
Lymph
Node
P118 M 48 ADC Never L858R L858R L858R L858R 95 50
P036 M 57 ADC Ever L858R L858R L858R L858R 60 40
P038 M 44 ADC Ever L858R L858R L858R L858R 80 80
P042 F 60 ADC Never L858R L858R L858R L858R 90 90
P009 F 49 ADC L858R WT L858R L858R 80 60
P062 F 56 ADC Ever L858R WT L858R L858R 70 70
P060 M 55 ADC Ever L858R WT L858R L858R 70 90
P111 F 61 ADC Never L858R WT L858R L858R 95 70
P011 M 48 ADC Ever L858R WT L858R WT 50 70
P018 F 44 ADC Never L858R WT L858R WT 70 50
P013 F 70 ADC Never L858R WT EGFR deletion WT 60 60
P015 F 68 ADC Never 2300_2308ins 2306_2314ins EGFR ins EGFR ins 90 60
P049 F 43 ADC Ever 2236_2250del 2236_2250del EGFR deletion EGFR deletion 60 60
P076 F 70 ADC Never 2236_2250del 2236_2250del EGFR deletion EGFR deletion 95 50
P003 F 64 ADC Never 2235_2249del 2235_2249del EGFR deletion EGFR deletion 85 60
P114 M 39 ADC Never 2235_2249del 2235_2249del EGFR deletion EGFR deletion 95 90
P108 M 65 SQC Never 2239_2247del 2239_2247del EGFR deletion WT 95 70
P016 F 42 ADC Ever 2235_2249del WT EGFR deletion EGFR deletion 70 20
P085 F 63 SQC Ever 2239_2256del WT EGFR deletion WT 95 70
P089 M 69 ASC Ever 2236_2250del WT EGFR deletion WT 95 80
P099 M 42 ADC Never 2239_2247del WT EGFR deletion WT 95 60
P021 M 74 SQC Ever WT T790M WT WT 90 70
P012 M 68 SQC Ever WT WT EGFR deletion WT 80 90
P117 M 75 ADC Ever WT WT L858R L858R 95 60
P070 M 50 ADC WT WT L858R L858R 95 90
P072 F 60 ADC Never WT WT L858R L858R 95 80
P001 M 62 ADC Ever WT WT EGFR deletion EGFR deletion 50 90
P034 M 42 ADC Ever WT WT EGFR deletion EGFR deletion 60 30
P007 M 75 SQC WT WT EGFR deletion, WT WT 90 80
P094 M 60 SQC Ever WT WT EGFR deletion, L858 WT 95 80
P098 F 37 ADC Ever WT WT WT L858R 95 60
P029 M 51 ADC Ever WT WT WT EGFR deletion 70 60
P051 M 54 SQC Ever WT WT WT EGFR deletion 40 90
P057 M 56 SQC Ever WT WT WT EGFR deletion 50 50
P047 M 75 ADC Ever WT WT WT EGFR deletion 90 50
P097 F 69 ADC Never WT WT WT EGFR deletion 95 70
P104 F 62 ADC Never WT WT WT EGFR deletion 95 90
EGFR, epidermal growth factor receptor; ADC, adenocarcinoma; SQC, squamous cell carcinoma; WT, wild type.
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Comparison of the EGFR Mutations between
Primary Tumors and Lymph Node Metastases
by Heteroduplex Analysis
Seventeen (16.8%) cases were discordant in the pres-
ence of EGFR mutations by heteroduplex analysis. Ten cases
(9.9%) were lymph node negative and primary tumor posi-
tive, whereas seven cases (6.9%) were lymph node positive
and primary tumor negative (Spearman’s correlation coeffi-
cient  0.577, p  0.0001).
The Correlation of EGFR Mutation Status and
Patients’ Characteristics
The clinical characteristics of the EGFR mutation-
positive and the EGFR mutation-negative patients were com-
pared. The EGFR mutation determined by direct DNA se-
quencing in the primary lung tumor was significantly
associated with female gender (p  0.001), never smokers
(p  0.026), and adenocarcinoma subtype (p  0.009).
However, there were no significant differences in clinical
characteristics between the patients with EGFR mutation
positive and negative lymph node metastasis. The EGFR
mutation-positive primary tumor determined by heteroduplex
analysis showed significant correlation with female gender
(p  0.015) and adenocarcinoma subtype (p  0.025).
Similar association was observed between the patients with
EGFR mutation-positive lymph node metastasis determined
by heteroduplex analysis.
DISCUSSION
To the best of our knowledge, this is the first report
comparing the EGFR mutations in pairs of primary NSCLC
with synchronous metastases in the regional lymph nodes
using both direct DNA sequencing and heteroduplex analysis
techniques. To our surprise, our results demonstrated that
tumor cells metastasized to the lymph nodes do not always
carry the same EGFR mutations as the primary NSCLC.
Previously, Italiano et al. demonstrated that a signifi-
cant proportion of the patients with NSCLC showed discor-
dance in EGFR status between primary tumor and metastases,
suggesting that EGFR expression might not be stable during
metastasis progression. Thirty-three percent of the cases (10
of 30) showed primary tumor versus corresponding metasta-
sis discordance by immunohistochemistry analysis and 27%
(7 of 26) by fluorescence in situ hybridization, respectively.22
Recently, this discordance also has been demonstrated by
other studies, showing that EGFR gene copy number by
fluorescence in situ hybridization is discrepant between pri-
mary NSCLC and the corresponding distant metastatic sites
in a considerable proportion of cases (32%, 9 of the 28).23
It is not known yet whether the discrepancy in EGFR
mutations between primary tumors and metastatic lymph
nodes is attributable to technical limitations of the methods
used for the assessment of EGFRmutations or to intratumoral
heterogeneity in EGFR mutations or to changes in EGFR
mutations during disease progression.
Although direct sequencing has been widely used to
evaluate the EGFR mutations, false negative results can be
caused when samples containing less than 30% tumor cells
was used for detection of a mutation.24 In this study, two
cases having less than 50% of tumor cells showed discrep-
ancy in the EGFR mutations between primary tumor and
metastatic lymph nodes by either direct sequencing or het-
eroduplex method. One case with less than 50% of tumor
cells only in the primary tumor sample showed EGFR muta-
tion only in metastatic lymph node by heteroduplex analysis.
The other case revealed EGFR mutation only in the primary
tumor by direct sequencing containing less than 50% tumor
cells in the metastatic lymph node. Because the specimens
contain a mixture of tumor and normal cells, the amount of
tumor cells in each specimen may affect the sensitivity of
analysis of EGFR mutations, and the discordance in EGFR
mutations may be partially attributable to false negative results.
To detect EGFRmutations in a small fraction of mutant
genes in specimens containing a mixture of tumor and normal
cells, various methods such as mutant-enriched PCR assay,25
single-strand conformation polymorphism analysis,26 Light-
Cycler PCR assay,27 and denaturing high-performance liquid
chromatography analysis18,28 were investigated. In addition,
laser capture microdissection to obtain purified tumor cell
populations from complex primary tissues may allow more
efficacious and precise identification of EGFR mutations.29
Although the best method for identifying EGFR mutations
has not yet been defined, it has been demonstrated that
previously established heteroduplex analysis is more sensi-
tive than direct sequencing for detecting EGFR mutations
when used with undissected formalin-fixed, paraffin-embed-
ded specimens.18,28 The sensitivity and specificity of the
heteroduplex method using Surveyor and the WAVE HS
denaturing high-performance liquid chromatography system
as a method for EGFR mutation detection were measured as
100% and 87%, compared with direct DNA sequencing in a
previous study.18 Of note, 4% of additional mutations that
were not detected by direct sequencing were detected by the
heteroduplex method.18 Even though additional EGFR muta-
tions were detected in 8 cases in primary tumors and in 15
cases in lymph node metastasis, respectively, by using more
sensitive heteroduplex analysis, the discordances in EGFR
mutations between primary and metastatic lymph node were
also observed in a considerable portion of the cases. These
results indicate that the discordance in EGFRmutations between
primary and metastatic tumors may not be attributable to differ-
ent technical methods for the detection of EGFR mutations.
Studies of heterogeneity in tumors clearly show that
there is extensive cytogenetic, genetic, and epigenetic vari-
ability in neoplastic cell populations in a variety of human
cancers,30,31 and the heterogeneity of cancer cell populations
in different metastasis site was also has been described.32,33
Previously, Reymond and coworkers34 suggested that
disseminated cancer cells are not always clonal with the
primary tumor, when comparing the pattern of K-ras muta-
tions between bone marrow micrometastases and correspond-
ing primary tumor. Recently, several differential gene or protein
expression studies have suggested that a selected population of
disseminated cancer cells and the primary tumors express a
considerable degree of heterogeneity.35,36 It has been also re-
ported that by comparative genomic hybridization, genetic het-
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erogeneity, and chromosomal imbalances are noted in the 7p11
region, where the EGFR gene is mapped.15
Our results demonstrate that, at least for EGFR muta-
tions determined by direct DNA sequencing or heteroduplex
analysis, disseminated cancer cells are not always identical
with the primary tumor in NSCLC. However, it is uncertain
whether molecular heterogeneity is a consequence of genetic
instability during metastatic spread of tumor cells or intratu-
moral heterogeneity of the primary tumors. Further studies
are warranted to elucidate whether the EGFR mutations main-
tain in a stable way during metastasis or there is any intratumoral
heterogeneity of EGFR mutation status in NSCLC.
These discordant results of EGFR mutations between
primary tumors and metastatic tumors may have therapeutic
implications for EGFR-targeted therapy strategies. Given that
EGFR mutation status is considered as a positive predictive
marker of response to TKI therapy, the results of EGFR
mutation according to the site of the biopsy specimens (pri-
mary versus metastatic) should be cautiously interpreted. In
cases of relapsed NSCLC after surgical resection, altered EGFR
mutations during tumor progression also should be considered in
making the decision for EGFR inhibitor-based therapy. Given
the possible heterogeneity of the EGFR mutations status, deter-
mination of the EGFR status using metastatic lesion or circulat-
ing tumor cells might be considered in making a decision for
EGFR inhibitor-based therapy. Further study will be required to
ascertain the potential importance of heterogeneity in EGFR
mutations in determining clinical response to TKIs.
ACKNOWLEDGMENTS
Supported in part by a grant of the Korean Health 21
R&D Project, Ministry of Health and Welfare, and Republic
of Korea (0405-MN01-0604-0007).
REFERENCES
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA
Cancer J Clin 2005;55:74–108.
2. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal
growth factor receptor family in lung cancer and premalignancy. Semin
Oncol 2002;29:3–14.
3. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor
receptor mutations in lung cancer. Nat Rev 2007;7:169–181.
4. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor
receptor (EGFR) activation and response to gefitinib and other EGFR-
targeting drugs. Clin Cancer Res 2006;12:7242–7251.
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized
phase II trial of gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin
Oncol 2003;21:2237–2246.
6. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor
of the epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: a randomized trial. JAMA
2003;290:2149–2158.
7. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular
and clinical predictors of outcome. N Engl J Med 2005;353:133–144.
8. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in
previously treated patients with refractory advanced non-small-cell lung
cancer: results from a randomised, placebo-controlled, multicentre study
(Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–1537.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously
treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the
epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
11. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A
2004;101:13306–13311.
12. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of
epidermal growth factor receptor mutation in non-small-cell lung cancer
patients treated with gefitinib. J Clin Oncol 2005;23:2493–2501.
13. Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomized, open-
label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in
clinically selected patients with advanced non small cell lung cancer
(IPASS). Ann Oncol 2008;19(Suppl 8):LBA2.
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004;304:
1497–1500.
15. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen
I. Chromosomal alterations in the clonal evolution to the metastatic stage
of squamous cell carcinomas of the lung. Br J Cancer 2000;82:65–73.
16. Ubagai T, Matsuura S, Tauchi H, Itou K, Komatsu K. Comparative
genomic hybridization analysis suggests a gain of chromosome 7p
associated with lymph node metastasis in non-small cell lung cancer.
Oncol Rep 2001;8:83–88.
17. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor
heterogeneity of epidermal growth factor receptor mutations in lung
cancer and its correlation to the response to gefitinib. Cancer Sci
2008;99:929–935.
18. Ja¨ nne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic
method for epidermal growth factor receptor mutation screening. Clin
Cancer Res 2006;12:751–758.
19. Ginsberg RJ. Resection of non-small cell lung cancer: how much and by
what route. Chest 1997;112:203S–205S.
20. Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node
dissection improves survival in patients with stages II and IIIa non-small
cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac
Surg 2000;70:358–365; discussion 365–366.
21. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histologic
Typing of Tumours of Lung and Pleura: World Health Organization Interna-
tional Classification of Tumors, 3rd Ed. New York: Springer Verlag, 1999.
22. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal
growth factor receptor gene and protein in primary non-small-cell-lung
cancer and metastatic sites: implications for treatment with EGFR-
inhibitors. Ann Oncol 2006;17:981–985.
23. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal
growth factor receptor (EGFR) gene expression in primary non-small
cell lung cancer (NSCLC) and in fine-needle aspirates from distant
metastatic sites. J Thorac Oncol 2008;3:18–22.
24. Fan X, Furnari FB, Cavenee WK, Castresana JS. Non-isotopic silver-
stained SSCP is more sensitive than automated direct sequencing for the
detection of PTEN mutations in a mixture of DNA extracted from
normal and tumor cells. Int J Oncol 2001;18:1023–1026.
25. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene
mutation in lung cancer by mutant-enriched polymerase chain reaction
assay. Clin Cancer Res 2006;12:43–48.
26. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-
cell lung cancer: analysis of a large series of cases and development of a
rapid and sensitive method for diagnostic screening with potential implica-
tions on pharmacologic treatment. J Clin Oncol 2005;23:857–865.
27. Sasaki H, Endo K, Konishi A, et al. EGFR mutation status in Japanese
lung cancer patients: genotyping analysis using LightCycler. Clin Can-
cer Res 2005;11:2924–2929.
28. Cohen V, Agulnik JS, Jarry J, et al. Evaluation of denaturing high-
performance liquid chromatography as a rapid detection method for
identification of epidermal growth factor receptor mutations in non-
small-cell lung cancer. Cancer 2006;107:2858–2865.
29. Giaccone G. EGFR point mutation confers resistance to gefitinib in a patient
with non-small-cell lung cancer. Nat Clin Pract Oncol 2005;2:296–297.
30. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and
clonal evolution underlying development of asynchronous metastasis in
human breast cancer. Cancer Res 1997;57:1597–1604.
31. Takahashi K, Kohno T, Matsumoto S, et al. Clonality and heterogeneity
of pulmonary blastoma from the viewpoint of genetic alterations: a case
report. Lung cancer 2007;57:103–108.
Park et al. Journal of Thoracic Oncology • Volume 4, Number 7, July 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer814
32. Gallegos Ruiz MI, van Cruijsen H, Smit EF, et al. Genetic heterogeneity
in patients with multiple neoplastic lung lesions: a report of three cases.
J Thorac Oncol 2007;2:12–21.
33. Rao UN, Jones MW, Finkelstein SD. Genotypic analysis of primary
and metastatic cutaneous melanoma. Cancer Genet Cytogenet 2003;
140:37–44.
34. Tortola S, Steinert R, Hantschick M, et al. Discordance between K-ras
mutations in bone marrow micrometastases and the primary tumor in
colorectal cancer. J Clin Oncol 2001;19:2837–2843.
35. Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of
carcinoma cells in the blood. Proc Nat Acad Sci U S A 1998;95:4589–4594.
36. Hayes DF, Walker TM, Singh B, et al. Monitoring expression of HER-2
on circulating epithelial cells in patients with advanced breast cancer. Int
J Oncol 2002;21:1111–1117.
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009Molecular Biomarkers in Primary NSCLC and Lymph Node Metastasis
Copyright © 2009 by the International Association for the Study of Lung Cancer 815
